An article published this year in “Scielo”
using our “Apoptosis Detection Kit FITC”, by our customers from several Centers, Hospitals
and Universities of Portugal, in the analysis of how Intestinal inflammatory
and redox responses to the perioperative administration of teduglutide in rats.
Congrats and Thanks.
Summay:
Glucagon-like peptide 2 (GLP-2) is a
gastrointestinal growth factor, synthetized in enteroendocrine L cells, that
exerts a relevant role on the control of energy absorption and the preservation
of intestinal mucosa morphology and function. Teduglutide is a
long-acting dipeptidylpeptidase IV-resistant equivalent of GLP-2 currently
accepted for pharmacological rehabilitation of patients with short-bowel syndrome
associated intestinal failure and also considered a promising medication
for moderate-to-severe Crohn’s disease. Several studies have
demonstrated that, in patients with short-bowel syndrome, teduglutide treatment
is safe, well tolerated and efficacious, with improvement of intestinal
absorption and reduction of parenteral support requirements. Teduglutide
was recently approved by the European Medicines Agency for treatment of
patients with short-bowel syndrome related parenteral support dependence
despite optimized medical and dietetic treatment, aged more than one year and
who are stable following a period of postsurgical intestinal adaptation.
Furthermore, in the recently published guidelines of the European Society for
Clinical Nutrition and Metabolism, teduglutide was considered the first choice
for carefully selected patients with chronic intestinal failure who are
candidates for growth factor treatment.
Reference:
Product link:
Apoptosis Detection Kit FITC
No comments:
Post a Comment